(R) -Bemcentinib

• Description:

  (R) -Bemcentinib ((R) -R428) is the R-isomer of Bemcentinib (HY-15150) . Bemcentinib (R428) is a selective, orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib blocks tumor metastasis and prolongs survival in metastatic breast cancer models[1][2][3].

• Product Name Alternative:

  (R) -R428; (R) -BGB324

• UNSPSC:

  12352005

• Hazard Statement:

  H302-H315-H319-H335

• Target:

  Drug Isomer

• Related Pathways:

  Others

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Smiles:

  NC=1N(C=2C=C3C(C=4C(CCC3)=CC=CC4)=NN2)N=C(NC=5C=C6C(=CC5)CC[C@H](CC6)N7CCCC7)N1

• Molecular Formula:

  C30H34N8

• Molecular Weight:

  506.66

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations:

  [1]Sensi M, et al. Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol. 2011 Dec;131 (12) :2448-57. |[2]Holland SJ, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 2010 Feb 15;70 (4) :1544-54.|[3]Lijnen HR, et al. Growth arrest-specific protein 6 receptor antagonism impairs adipocyte differentiation and adipose tissue development in mice. J Pharmacol Exp Ther. 2011 May;337 (2) :457-64.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  1037624-76-2